Research

N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial

Manouchehr Amini¹ , Mojtaba Salarifar² , Alireza Amirbaigloo³ , Farzad Masoudkabir⁴ and Fatemeh Esfahani³

¹  Department of nephrology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

²  Department of cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

³  Research Development Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁴  Student Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran

author email corresponding author email

Trials 2009, 10:45doi:10.1186/1745-6215-10-45

Published:	29 June 2009

Abstract

Background

Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) constitute to be a high-risk population for the development of contrast-induced nephropathy (CIN), in which the incidence of CIN is estimated to be as high as 50%. We performed this trial to assess the efficacy of N-acetylcysteine (NAC) in the prevention of this complication.

Methods

In a prospective, double-blind, placebo controlled, randomized clinical trial, we studied 90 patients undergoing elective diagnostic coronary angiography with DM and CKD (serum creatinine ≥ 1.5 mg/dL for men and ≥ 1.4 mg/dL for women). The patients were randomly assigned to receive either oral NAC (600 mg BID, starting 24 h before the procedure) or placebo, in adjunct to hydration. Serum creatinine was measured prior to and 48 h after coronary angiography. The primary end-point was the occurrence of CIN, defined as an increase in serum creatinine ≥ 0.5 mg/dL (44.2 μmol/L) or ≥ 25% above baseline at 48 h after exposure to contrast medium.

Results

Complete data on the outcomes were available on 87 patients, 45 of whom had received NAC. There were no significant differences between the NAC and placebo groups in baseline characteristics, amount of hydration, or type and volume of contrast used, except in gender (male/female, 20/25 and 34/11, respectively; P = 0.005) and the use of statins (62.2% and 37.8%, respectively; P = 0.034). CIN occurred in 5 out of 45 (11.1%) patients in the NAC group and 6 out of 42 (14.3%) patients in the placebo group (P = 0.656).

Conclusion

There was no detectable benefit for the prophylactic administration of oral NAC over an aggressive hydration protocol in patients with DM and CKD.

Trial registration

NCT00808795